Literature DB >> 36251167

A Renewed Charter: Key Principles to Improve Patient Care in Severe Asthma.

Andrew Menzies-Gow1,2, David J Jackson3, Mona Al-Ahmad4, Eugene R Bleecker5, Francisco de Borja G Cosio Piqueras6, Stephen Brunton7, Giorgio Walter Canonica8,9, Charles K N Chan10, John Haughney11, Steve Holmes12, Janwillem Kocks13,14,15, Tonya Winders16,17.   

Abstract

Asthma is a heterogenous respiratory disease, usually associated with chronic airway inflammation and hyper-responsiveness, which affects an estimated 339 million people worldwide. Severe asthma affects approximately 5-10% of patients with asthma, approximately 17-34 million people globally, more than half of whom have uncontrolled disease. Severe asthma carries a substantial burden of disease, including unpredictable symptoms and potentially life-threatening flare-ups. Furthermore, severe asthma has a substantial burden on health care systems and economies worldwide. In 2018, a group of experts from the clinical community, patient support groups, and professional organisations joined together to develop the Severe Asthma Patient Charter, which set out six principles to define what patients should expect for the management of their severe asthma and what should constitute a basic standard of care. Since the publication of that original Charter in 2018, several important changes have occurred, including an improved understanding of asthma and effective asthma management; several new therapies have become available; and finally, the COVID-19 pandemic has placed a spotlight on respiratory conditions, the workforces that treat them, and the fundamental importance of health care system resilience. With those developments in mind, we, representatives of the academic, clinical, and patient advocacy group communities, have updated the Charter to Improve Patient Care in Severe Asthma with a focus on six principles: (1) I deserve a timely, comprehensive assessment of my asthma and its severity; (2) I deserve a timely, straightforward referral to an appropriate specialist for my asthma when it is not well controlled; (3) I deserve to understand what makes my asthma worse; (4) I deserve access to treatment and care that reduces the impact of asthma on my daily life; (5) I deserve not to be reliant on systemic corticosteroids; (6) I deserve to be involved in decisions about my treatment and care.
© 2022. The Author(s).

Entities:  

Keywords:  Health care; Patient advocacy; Severe asthma

Year:  2022        PMID: 36251167      PMCID: PMC9573814          DOI: 10.1007/s12325-022-02340-w

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   4.070


  69 in total

1.  Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry.

Authors:  Eve Denton; David B Price; Trung N Tran; G Walter Canonica; Andrew Menzies-Gow; J Mark FitzGerald; Mohsen Sadatsafavi; Luis Perez de Llano; George Christoff; Anna Quinton; Chin Kook Rhee; Guy Brusselle; Charlotte Ulrik; Njira Lugogo; Fiona Hore-Lacy; Isha Chaudhry; Lakmini Bulathsinhala; Ruth B Murray; Victoria A Carter; Mark Hew
Journal:  J Allergy Clin Immunol Pract       Date:  2021-03-18

2.  Parent-reported outcomes of a shared decision-making portal in asthma: a practice-based RCT.

Authors:  Alexander G Fiks; Stephanie L Mayne; Dean J Karavite; Andrew Suh; Ryan O'Hara; A Russell Localio; Michelle Ross; Robert W Grundmeier
Journal:  Pediatrics       Date:  2015-03-09       Impact factor: 7.124

Review 3.  Sustainability in Inhaled Drug Delivery.

Authors:  Alexander J K Wilkinson; Greg Anderson
Journal:  Pharmaceut Med       Date:  2020-06

4.  Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study.

Authors:  Thomas B Casale; Allan T Luskin; William Busse; Robert S Zeiger; Benjamin Trzaskoma; Ming Yang; Noelle M Griffin; Bradley E Chipps
Journal:  J Allergy Clin Immunol Pract       Date:  2018-05-22

5.  Short-acting β-agonist use and its ability to predict future asthma-related outcomes.

Authors:  Richard H Stanford; Manan B Shah; Anna O D'Souza; Amol D Dhamane; Michael Schatz
Journal:  Ann Allergy Asthma Immunol       Date:  2012-10-01       Impact factor: 6.347

6.  Oral corticosteroid use, morbidity and mortality in asthma: A nationwide prospective cohort study in Sweden.

Authors:  Magnus Ekström; Bright I Nwaru; Pål Hasvold; Fredrik Wiklund; Gunilla Telg; Christer Janson
Journal:  Allergy       Date:  2019-06-11       Impact factor: 13.146

7.  The Projected Economic and Health Burden of Uncontrolled Asthma in the United States.

Authors:  Mohsen Yaghoubi; Amin Adibi; Abdollah Safari; J Mark FitzGerald; Mohsen Sadatsafavi
Journal:  Am J Respir Crit Care Med       Date:  2019-11-01       Impact factor: 21.405

8.  Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis.

Authors:  Marlene Bloechliger; Daphne Reinau; Julia Spoendlin; Shih-Chen Chang; Klaus Kuhlbusch; Liam G Heaney; Susan S Jick; Christoph R Meier
Journal:  Respir Res       Date:  2018-04-27

9.  Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis.

Authors:  Tim Harrison; Giorgio Walter Canonica; Geoffrey Chupp; Jason Lee; Florence Schleich; Tobias Welte; Antonio Valero; Kim Gemzoe; Aoife Maxwell; Sandra Joksaite; Shibing Yang; Peter Howarth; Melissa K Van Dyke
Journal:  Eur Respir J       Date:  2020-10-15       Impact factor: 16.671

10.  Environmental Sustainability in Respiratory Care: An Overview of the healthCARe-Based envirONmental Cost of Treatment (CARBON) Programme.

Authors:  Alex Wilkinson; Ekaterina Maslova; Christer Janson; Yang Xu; John Haughney; Jennifer K Quint; Nigel Budgen; Andrew Menzies-Gow; John Bell; Michael G Crooks
Journal:  Adv Ther       Date:  2022-03-13       Impact factor: 4.070

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.